Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

How Prostate Cancer Cells Use Strategy Instead of Brute Force to Achieve Metastasis.

Tharp D, Nandana S.

Cancers (Basel). 2019 Dec 3;11(12). pii: E1928. doi: 10.3390/cancers11121928. Review.

2.

Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.

Chu GC, Chung LWK, Gururajan M, Hsieh CL, Josson S, Nandana S, Sung SY, Wang R, Wu JB, Zhau HE.

Asian J Urol. 2019 Jan;6(1):65-81. doi: 10.1016/j.ajur.2018.11.003. Epub 2018 Nov 28. Review.

3.

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Tripathi M, Nandana S, Billet S, Cavassani KA, Mishra R, Chung LWK, Posadas EM, Bhowmick NA.

Oncotarget. 2017 Sep 23;8(50):87891-87902. doi: 10.18632/oncotarget.21248. eCollection 2017 Oct 20.

4.

Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.

Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, Zhau HE, Matusik RJ, Chung LW.

Cancer Res. 2017 Mar 15;77(6):1331-1344. doi: 10.1158/0008-5472.CAN-16-0497. Epub 2017 Jan 20.

5.

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.

Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM.

Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398.

6.

Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.

Nandana S, Chung LW.

Am J Clin Exp Urol. 2014 Jul 12;2(2):92-101. eCollection 2014. Review.

7.

miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer.

Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW.

Clin Cancer Res. 2014 Sep 1;20(17):4636-46. doi: 10.1158/1078-0432.CCR-14-0305. Epub 2014 Jun 24.

8.

Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R.

Prostate. 2010 May 1;70(6):591-600. doi: 10.1002/pros.21093.

9.

Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer.

Yi Y, Nandana S, Case T, Nelson C, Radmilovic T, Matusik RJ, Tsuchiya KD.

Mol Cytogenet. 2009 Sep 26;2:18. doi: 10.1186/1755-8166-2-18.

10.

Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V.

J Biol Chem. 2008 Nov 7;283(45):30576-84. doi: 10.1074/jbc.M802312200. Epub 2008 Sep 9.

11.

Prostate epithelial cell fate.

Matusik RJ, Jin RJ, Sun Q, Wang Y, Yu X, Gupta A, Nandana S, Case TC, Paul M, Mirosevich J, Oottamasathien S, Thomas J.

Differentiation. 2008 Jul;76(6):682-98. doi: 10.1111/j.1432-0436.2008.00276.x. Epub 2008 May 7. Review.

PMID:
18462434
12.

PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity.

Levitin F, Weiss M, Hahn Y, Stern O, Papke RL, Matusik R, Nandana SR, Ziv R, Pichinuk E, Salame S, Bera T, Vincent J, Lee B, Pastan I, Wreschner DH.

J Biol Chem. 2008 Jun 13;283(24):16928-39. doi: 10.1074/jbc.M801454200. Epub 2008 Apr 3.

13.

Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases.

Kenchappa P, Yadav A, Singh G, Nandana S, Banerjee K.

J Neurosci Res. 2004 May 15;76(4):466-74.

PMID:
15114618

Supplemental Content

Loading ...
Support Center